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INTRODUCTION 
 Acute Coronary Syndrome is one of the leading causes of mortality in our 
country. With the increasing incidence of Diabetes and metabolic syndrome, we 
are encountering more cases of myocardial infarction  with increasing severity. 
For the past two decades, there has been an increasing trend of chronic 
metabolic diseases globally against a back drop of infectious diseases. This 
epidemiological transition has been described as three basic stages by Omran : 
Pestilence and famine, Receding pandemics, Manmade and degenerative 
diseases. Olshansky1 added a fourth stage, delayed degenerative diseases. 
FOUR STAGES OF EPIDEMIOLOGICAL TRANSITION (TABLE1) 
STAGE 
PROPORTION 
OF DEATHS 
DUE TO CVD 
MAJOR TYPE OF CVD 
Pestilence 
&famine <10% 
RHD, Cardiomyopathy due to malnutrition 
and infection 
Receding 
Pandemics 10-35% RHD, Hypertension, CAD, Stroke 
Degenerative  
diseases 35-65% Stroke , CAD 
Delayed 
degenerative 
diseases 
40-50% Stroke, CAD, Congestive cardiac failure 
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GLOBAL BURDEN OF CAD  1             
 Of the 45 million adult deaths reported in 2002, more than three quarters 
were due to non-communicable diseases(WHO 2003)30.  In the twentieth 
century, less than 10% of deaths were due to coronary artery disease. By the 
beginning of 21 st century, CAD accounted for almost half of all deaths in the 
developed world and 25% in the developing world2. By 2020, it has been 
predicted that CAD will claim about 25 million lives annually around the world.  
 Globally, Ischaemic Heart Disease was the leading killer in the age group 
>60 years. In adults aged 15-59 years, Ischaemic Heart Disease was the second 
leading cause of mortality, second only to HIV/AIDS1.  
 Although the use of  prediction models like the Framingham’s study  
greatly increases the detection of atherosclerotic risk, about 20% of myocardial 
infarction occurs in the absence of classical vascular risk factors.  Many trials 
have been conducted to identify novel markers and risk factors of 
atherosclerosis.  Similarly, there are only a few clinical predictors of prognosis 
in acute coronary syndromes (the Killip staging ,TIMI and GRACE scores) . 
The need for biochemical cardiac markers in predicting major adverse cardiac 
events (MACE) and mortality  has been realized in the recent past.  Recent 
studies have focussed on the prognostic significance of novel markers like hs- 
CRP, lipoprotein a, homocysteine,   BNP, IL-6  and uric acid . 
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 Uric acid is a marker of oxidative stress that reflects the inflammatory 
process occuring in atherosclerotic plaques and has also been linked to 
endothelial dysfunction and cell death. It is one of the most studied markers in 
ACS and other multifactorial diseases like obesity, hypertension, metabolic 
syndrome and stroke. Studies have ended up with conflicting results, with some 
studies showing a strong correlation, while others have not demonstrated a clear 
association. Similarly, a few studies carried out in populations with acute 
coronary syndrome have shown that uric acid is an independent marker of 
adverse cardiac outcomes in both short term and long term, while some studies 
refute it.  
 In this study, we have focussed on the association of uric acid with 
various clinical prognostic indicators, major adverse cardiac events(MACE) and 
mortality in patients presenting with acute ST Elevation MI 
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AIMS OF THE STUDY 
• To assess the prevalence of hyperuricemia in patients with Acute ST 
Elevation MI 
• To study the association of uric acid levels with various risk factors of 
cardiovascular disease in these patients 
• To study the association of uric acid levels with Killip Class, TIMI risk 
score and adverse cardiac events 
• To assess the usefulness of uric acid as an independent prognostic marker 
of short term mortality in Acute STEMI 
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REVIEW OF LITERATURE 
CAD - TRENDS IN INDIA 
 In India, CAD incidence is on the rising scale for the past 40 years 
whereas a declining trend has been noted in the western countries. Mortality due 
to CAD is expected to rise by 103% in Indian men and 90% in women from 
1975 to 2015.(Bulatao and Stephens 1992)  .       
 The Study of Health Assessment and Risk in Ethnic groups(SHARE) has 
reported a higher incidence of cardiovascular events among South Asians when 
compared to Europeans and Chinese3 .   Asian Indians are at three times higher 
risk of CAD than white Americans, six times higher than Chinese and 20 times 
higher than Japanese.(Ghaffar et al. 2004) . The SHARE study showed that 
atherosclerosis was higher among Europeans while thrombosis was higher 
among South Asians, suggesting a thrombogenic profile prevailing among 
South Asian population3. A study in the South East Asian population by 
Meenakshisundaram et al has brought out that many subjects had an MI even in 
the presence of low BMI and interestingly, dyslipidemia was not present in 
most of the studied population27. This may be seen in two perspectives: South 
East Asians have a lower BMI threshold to be called obese. Many other studies 
have also brought out this fact. Hence the ideal BMI in this population is <23 
kg/m2. People with a BMI of more than 23 may be called overweight and >25 as 
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obese27. This result may also indicate an existing thrombogenic profile in the 
South East Asian population. 
 However, the INTERHEART study, one of the largest case control 
studies,  has not proved any ethnic risk factors in South Asians29. This study 
explained that traditional risk factors like smoking, alcoholism, diabetes, 
hypertension, high waist-hip ratio, dyslipidemia, sedentary life style accounts 
for more than 90% of CAD events in South Asians.The ICMR study performed 
in Delhi and Vellore in 1990s reported higher prevalence of CAD in North 
India29.  
TRENDS IN TRADITIONAL CARDIOVASCULAR  RISK FACTORS                           
 Diabetes, hypertension, dyslipidemia, triglyceridemia, metabolic 
syndrome, smoking , alcoholism, family history of myocardial infarction are the 
traditional risk factors.  
 A 35 year trend in BMI, systolic BP and cholesterol has been reported 
from 199 high income, low income and middle income countries by the Global 
Burden of Diseases Chronic Disease Risk Factors Collaborating Group1 from 
1980-2005. A trend for increasing BMI was noted in all these countries, with 
greater rise in  high income countries. Mean systolic BP increased in low 
income countries and dropped in high and middle income countries4. Mean 
cholesterol levels increased in the low income countries and came down in low 
7 
 
and middle income countries. In India , data is similar to that in low income 
countries. 
 Epidemiological studies performed in various states have shown that 
obesity , hypertension, self reported diabetes are common in Kerala and Tamil 
Nadu, while smoking is common in Mizoram. In India, the cardiovascular risk 
factors are more prevalent in the urban areas in contrast to the western countries 
where it is equal in both urban and rural population29 
NOVEL RISK FACTORS 
CRP5  
 CRP has long been recognised as an inflammatory marker and it provides 
an indirect evidence of the inflammatory milieu of atherosclerosis. Emerging 
evidence shows that CRP has a direct causal effect on  atherosclerosis31. CRP 
binds to oxidized LDL, promoting its uptake by the macrophages in the 
atherosclerotic plaque ,  thereby perpetuating the process5. hs-CRP levels help 
us to start statin therapy in high risk individuals. simvastatin reduces CRP levels 
even before it reduces LDL levels.        
LIPOPROTEIN a 
 Lp(a) is a similar molecule as LDL except for the addition of 
apolipoprotein --apo(a).  It resembles plasminogen5 in structure and thereby 
thought to play a role in thrombosis. It also accumulates in atherosclerotic 
plaques . It binds to thrombin and decreases the fibrinolytic activity of plasmin. 
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Lp (a) >30 mg/dl increases the cardiovascular risk5)31. Niacin is the only 
available drug that reduces the level of Lp(a).          
HOMOCYSTEINE 
 Homocysteine impairs the production of endothelial nitric oxide, 
increases the proliferation of smooth muscle cells in the atherosclerotic plaque 
and activates protein c5, thereby promoting thrombosis.   
FIBRINOGEN 
 It is a protein synthesized in liver, that activates thrombin, stimulates 
platelet aggregation, and increases smooth muscle proliferation in the 
atherosclerotic plaque. Age, menopause, smoking, stress, obesity increases the 
levels of fibrinogen. Pentoxifylline, omega 3 fatty acids, fibrates, ticlopidine 
reduces the fibrinogen levels. 
MYELOPEROXIDASE 
 MPO is released during degranulation of leucocytes in an atherosclerotic 
plaque. It has been shown to predict the 30 day mortality after NSTEMI. Levels 
of myeloperoxidase increase with endothelial dysfunction. It has been observed 
that myeloperoxidase is an even stronger predictor of cardiovascular events than 
CRP32.  
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ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE 
 Experimental results in animals and humans have shown that fatty streak 
is the initial  manifestation of atherosclerosis. This has been increasingly 
recognised as an inflammatory process resulting in the formation of reactive 
oxygen species and endothelial damage50. LDL particles accumulate within the 
intima and associate with proteoglycans in the extracellular matrix. This 
sequestration favours oxidative modification of lipoproteins, which trigger an 
inflammatory reaction, that results in leucocyte recruitment. The leucocytes 
exhibit receptors for modified lipoproteins and start ingesting more oxidised 
lipids and transform into foam cells. As the lesion evolves, smooth muscle cells 
from the media migrate into the expanding intima and lay down an extracellular 
matrix there and form an atherosclerotic plaque. In the heart, atherosclerotic 
process shows a predilection for the proximal left anterior descending artery50. 
PLAQUE RUPTURE 
    A superficial erosion of the endothelium or a plaque rupture produces a 
thrombus that occludes the vessel and causes an acute coronary syndrome due 
to the lack of a well formed collateral circulation. Morphometric studies of 
these atherosclerotic plaques have shown that macrophages and lymphocytes 
predominate in these lesions rather than the smooth muscle cells. Patients with 
active atherosclerotic process and those with acute coronary syndromes exhibit 
markers of diffuse inflammation( Braunwald), that is, even the atherosclerotic 
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plaques and endothelial cells remote from the culprit lesion exhibit markers of 
inflammation51. The integrity of the plaque is decided by these inflammatory 
markers. IFN gamma found in these lesions inhibits the proliferation of smooth 
muscle cells. Cytokines produced by activated leucocytes increase the formation 
of proteolytic enzymes that degrade the matrix of the fibrous cap. Thus these 
inflammatory mediators inhibit the collagen synthesis required for the repair of 
the eroded fibrous cap and also makes it thin and prone for rupture (hence called 
the vulnerable plaques). These plaques have a thin fibrous cap and matrix and  
more inflammatory cells, that trigger  thrombotic and fibrinolytic processes, 
which cause acute arterial occlusion and result in acute coronary syndrome. 
 This knowledge about pathogenesis of atherosclerosis is very important 
in identifying newer mechanisms linking it to various risk factors and the ways 
in which current therapies improve outcomes and in finding out newer 
therapeutic targets.  
ACUTE CORONARY SYNDROME 
 Patients with ischaemic heart disease fall into two categories : Stable 
angina and Acute coronary syndromes(ACS). ACS can be subdivided into three 
groups based on the ECG findings and cardiac markers: ST elevation MI;  Non 
ST elevation MI and Unstable angina. Unstable angina and NSTEMI occur due 
to plaque erosion or rupture with a non occlusive thrombus. They are usually 
caused by platelet thrombi (white thrombi) whereas STEMI is usually caused by 
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fibrin thrombi(red thrombi). When patients present with non ST elevation ACS , 
cardiac markers are helpful in differentiating unstable angina and NSTEMI. 
Patients with UA/NSTEMI usually have multiple vulnerable plaques. 
 Patients with unstable angina and multiple risk factors are at increased 
risk of developing ST elevation MI. ST elevation is produced by complete 
occlusion of an epicardial coronary artery.  While evaluating a STEMI, we have 
to consider the temporal phase of the infarction: a) acute phase, lasting from the 
first few hours to 7 days; b)healing phase- 7 to 28 days ; c)healed phase ->29 
days. 
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CLINICAL CLASSIFICATION OF MYOCARDIAL INFARCTION5           
(J Am Coll Cardiol  2007)           
 TYPE 1  – Spontaneous MI related to ischaemia from a coronary plaque  
  rupture     or dissection 
TYPE 2  – MI due to ischaemia resulting from invreased oxygen demand or 
  decreased supply 
TYPE 3  – Sudden cardiac death with symptoms of ischaemia, new ST  
  elevation, or LBBB or coronary thrombus 
TYPE 4a  – MI associated with PCI 
TYPE 4b  – MI associated with stent thrombosis 
TYPE 5  – MI associated with CABG  
 
 FIBRINOLYTIC THERAPY IN STEMI 
 Fibrinolytic therapy reduces the risk of mortality in STEMI by 50% while 
administered within an hour of onset of symptoms . When administered early, 
fibrinolytic therapy reduces the infarct size, limits LV dysfunction, reduces the 
incidence of complications of STEMI like ventricular septal rupture, 
arrhythmias and cardiogenic shock. It is proved to be of benefit when 
administered within 6 hours of onset of symptoms. But still, some patients may 
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benefit till a period of 12 hours, especially when the pain is persisting or ST 
segment remains elevated13. Patients < 75 years of age attain greater risk 
reduction with fibrinolytic therapy when compared to older individuals53. 
 
MAJOR ADVERSE CARDIAC EVENTS 
 The following are the commonest adverse cardiac events occuring in 
patients with ST elevation MI53: 
1. Ventricular dysfunction        
2.  Pump failure 
3.  Cardiogenic shock 
 4. Right ventricular infarction 
5. Arrhythmias 
6. Recurrent angina 
7. Pericarditis 
8. Thromboembolism 
9. Left ventricular aneurysm 
10. Reinfarction 
11. Ventricular septal rupture 
12. Free wall rupture 
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ARRHYTHMIAS 
 Arrhythmias are the most common complications of myocardial 
infarction. Various rhythm disturbances occuring during MI include ventricular 
premature beats, accelerated idioventricular rhythm,  ventricular tachycardia, 
ventricular fibrillation, sinus bradycardia,atrioventricular and intraventricular 
conduction disturbances. Among these, ventricular premature beats are 
commonly encountered . According to current guidelines , prophylactic anti 
arrhythmic drugs are contraindicated unless a clinically important ventricular 
arrhythmia occurs.  Beta blockers are ideal in case of frequent ventricular 
premature beats. Accelerated idioventricular rhythm or slow VT occurs 
transiently during thrombolytic therapy and is benign and does not lead to 
ventricular tachycardia13. Sinus bradycardia and atrioventricular conduction 
blocks occurs most commonly in inferior wall MI and may require pacing . 
 
LV FAILURE AND CARDIOGENIC SHOCK 
 Hemodynamic evidence of LV dysfunction  appears when left ventricular 
contraction is impaired in 20-25% of the ventricle. >40% of left ventricular 
infarction results in cardiogenic shock53. Patients with acute MI and cardiogenic 
shock usually have triple vessel disease with frequent involvement of LAD. 
40% of patients with shock have previous history of MI. Other causes of 
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cardiogenic shock in MI are right ventricular infarction, ventricular septal 
rupture, acute mitral regurgitation, cardiac tamponade and free wall rupture. 
 
POST- MYOCARDIAL INFARCTION RISK STRATIFICATION 
 After diagnosing a myocardial infarction, a physician’s goal must be to 
risk stratify patients, treat complications and to initiate risk factor modification.  
The following factors help to predict inhospital mortality and recurrent cardiac 
events 
 
PREDICTORS OF IN HOSPITAL MORTALITY53 
1. older age 
2. tachycardia 
3. hypotension 
4. Killip class>1 
5. Anterior wall infarction 
6. Previous infarction 
7.  LV dysfunction and Heart failure   
8. Malignant arrhythmias like supraventricular tachycardia, ventricular 
fibrillation and ventricular fibrillation  
9. Elevated initial serum creatinine  
10. Persistent chest pain or early angina on minimal exertion 
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11. New ST segment changes either depression or elevation 
12. Severe coronary artery disease 
13. Poor glycemic control 
14. Anaemia  
AGE 
 Age is the most important mortality predictor post MI. Older patients are 
at risk of recurrent MI and the mortality rates are higher in the elderly. More 
number of older individuals present with atypical symptoms and the risk of 
bleeding is also high in the elderly, when compared to younger individuals. 
KILLIP STAGING 
 Killip and Kamball described four classes in MI based on clinical 
presentation and hemodynamic status. This helps to assess the prognosis of 
patients presenting with MI. 
KILLIP CLASS CLINICAL FINDINGS MORTALITY  
I No evidence of CCF 5.1% 
II Rales/ raised JVP/S3 13.6% 
III Pulmonary edema 32.2% 
IV Cardiogenic shock 57.8% 
 
TABLE 2 
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LV FUNCTION 
 This is the second most important predictor of mortality. Ejection 
fraction<40% is associated with a poor prognosis. Usually, shock occurs when 
atleast 40% of the left ventricular mass  undergoes infarction53. But recent 
studies have shown that shock occurs due to inappropriate vasodilatation 
combined with ventricular dysfunction. The raised inflammatory markers and 
nitric oxide synthase suggest a systemic inflammatory response syndrome that 
is responsible for sustaining the cardiogenic shock.  There are various available 
options for assessing left ventricular function . These include echocardiography, 
radionuclide angiography and left ventriculography. No modality has been 
proved superior to the other but cost and availability are important determinants. 
Echocardiography is the most commonly used imaging modality. 
 
CARDIAC MARKERS 
 A few cardiac markers have been found useful in risk stratification of 
acute MI patients. Among the traditional markers, CK MB has the disadvantage 
of a short half life, though higher levels are associated with high mortality rates. 
Troponin, B-type natriuretic peptide and  C- Reactive Protein have been found 
to predict future cardiac events.  
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 OTHER FACTORS 
 Women have a later age of onset of MI but the mortality rates remain the 
same in both men and women. Women have higher risk of bleeding. 
 Patients with diabetes are at a higher risk of death and adverse events , 
but the treatment in both groups is the same. Anti platelet agents have a 
consistent or  enhanced effect in patients with diabetes.  
 About 30-40% of the patients with MI have renal dysfunction and is 
associated with a bad prognosis and increases the risk of bleeding. 
RISK MODELS IN ACUTE MYOCARDIAL INFARCTION                                      
 Certain risk scores have been formulated using the above mentioned 
factors to assess the prognosis of the patients presenting with STEMI.They are:  
1. TIMI score( Thrombolysis in Myocardial Infarction)      
2. The GRACE score ( Global Registry of Acute Coronary Events)      
3. The GISSI score( Gruppo Italiano per lo Studio della Sopravvivenza 
nell’Infarto Miocardio  
TIMI RISK SCORE IN STEMI33 
 David A. Morrow et al has formulated a simple, bedside, clinical score 
for risk assessment of ST elevation MI (Circulation 2000;102:2031-2037). This 
is a useful bedside method of predicting 30 day mortality in patients with 
STEMI. The risk score includes the following variables(TABLE 3) 
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SL NO VARIABLES SCORES 
1 
AGE    65-74 YEARS 2 
AGE> 75 YEARS 3 
2 SYSTOLIC BP<100 3 
3 HEART RATE>100 2 
4 KILLIP II-IV 2 
5 ANTERIOR STE OR LBBB 1 
6 DIABETES, H/O ANGINA/HYPERTENSION 1 
7 WEIGHT<67 kg 1 
8 TIME TO TREATMENT>4 HRS 1 
 
 This risk scoring was derived from patients with ST Elevation MI, 
eligible for thrombolysis. It has been observed that patients ineligible for 
thrombolysis were at higher risk of developing adverse cardiac events and 
hence were excluded from the trials. The 30 day mortality was 44% among 
those with TIMI score 0 and rose to 77% when TIMI score was more than 833. 
The maximum TIMI score that can be obtained is 14. 
 
ASSESSMENT OF RESIDUAL ISCHAEMIA 
 As seen already, severe CAD and recurrent angina are strong predictors 
of mortality in a patient with myocardial infarction53. So submaximal stress 
testing has been advocated for patients who are not in failure for at least 2 days 
and without any ongoing ischaemia. This helps to prognosticate patients with 
20 
 
MI. Patients who can ahcieve upto 3 METs carry a good prognosis. Usually 
exercise stress testing is done but in case of unpredictable ECG pattern like left 
bundle branch block, baseline ST segment changes or left ventricular 
hypertrophy, exercise stress testing is contraindicated and we have to go for 
pharmacological stress testing using dobutamine or adenosine. ACC 
recommends stress  testing within 72 hours of discharge in all patients with 
uncomplicated infarction53.   Significant ST segment   changes during exercise, 
hypotension or inability to achieve 3 METS is a sign of poor prognosis and such 
patients warrant coronary angiography. 
ROLE OF CARDIAC BIOMARKERS IN DIAGNOSIS AND RISK 
SRATIFICATION OF PATIENTS WITH MI 
 Laboratory evidence of myocardial necrosis is always an integral part in 
diagnosing and treating acute coronary syndrome. Cardiac biomarkers have 
been used in conjunction with history and ECG findings in order to confirm the 
diagnosis of myocardial infarction. An ideal marker has to be specific to the 
myocardium, sensitive, and quantitative and there should be an early rise in the 
serum levels of the markers. CPK-MB and Troponin are traditional cardiac 
biomarkers used at present to diagnose infarction. These markers have certain 
limitations. As myocardial necrosis is time dependent, these markers may be 
negative during initial presentation and may later turn out to be positive. 
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 When evaluating a novel marker physicians should consider whether 
1.there is a standardized and reproducible assay for the marker of interest;  
2.there are consistent prospective studies demonstrating that the given 
parameter predicts future risk; 3. The novel marker adds to the predictive value 
of lipid screening 4. There is evidence that it adds to global risk prediction 
scores like the Framingham’s study. Also to be considered is the relative 
magnitude of novel markers in terms of risk prediction, particularly in 
comparison to lipid profile. These markers may refine risk assessment and some 
of them have prognostic significance.   
 Among the traditional cardiac biomarkers, only troponin has a role in 
predicting adverse cardiac events. CPK MB has a short half life and is also 
relatively less specific for myocardial infarction.  Certain novel biomarkers, 
when measured in combination with CK-MB or troponin helps in risk 
stratification of patients with acute MI51. 
NOVEL BIOCHEMICAL CARDIAC MARKERS5 
1.MARKERS OF INFLAMMATION 
♦ Hs- CRP 
♦ Myeloperoxidase 
♦ Pregnancy associated plasma protein A, 
♦ Soluble CD-40 ligand 
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♦ Interleukin -6(IL-6) 
♦ VCAM , ICAM-1 
3. MARKERS OF HAEMODYNAMIC STRESS OR NEUROHORMONAL 
ACTIVATION 
♦ BNP, NT-pro BNP 
4. MARKERS OF VASCULAR DAMAGE 
♦ Creatinine Clearance 
♦ Cystatin C 
5. MARKERS OF ACCELERATED ATHEROSCLEROSIS 
♦ HbA1C 
6.  MARKERS OFTHROMBOSIS & PLATELET ACTIVATION 
♦ Von Willebrand factor antigen 
♦ Plasminogen Activator Inhibitor 1 
♦ Tissue- Plasminogen Activator 
♦ Fibrinopeptide A 
♦ Prothrombin fragment 1+2 
♦ Factors V,VII and VIII 
♦ D Dimer 
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 MARKERS OF INFLAMMATION & OXIDATIVE STRESS   
 Atherosclerosis is basically an inflammatory disease. Understanding the 
pathogenesis of atherosclerosis has led to a keen interest on the inflammatory 
markers that predict the risk of coronary artery disease. Inflammatory markers 
of atherosclerosis include  hs- CRP, lipoprotein (a), homocysteine, 
myeloperoxidase, soluble CD-40 ligand, IL-6,IL-18 and s ICAM-1 . As already 
mentioned, atherosclerosis and plaque rupture results in increase in the levels of 
these inflammatory markers which further create a pro oxidative milieu and 
makes the plaque unstable50. Among the inflammatory markers, CRP is the only 
proved prognostic marker till now. Myeloperoxidase has shown promising 
results in various studies and  has  been tried both as a diagnostic and prognostic 
marker. According to recent studies, elevated levels of MPO are associated with 
increased cardiovascular risk even in the presence of normal troponin and CRP 
levels5.  Thus MPO may be a more definite marker of future cardiovascular 
events when compared to Troponin and CRP.   
 Uric acid is a marker of oxidative stress and inflammation17. It has  been 
studied in various populations and many studies have established a strong 
association of uric acid levels with cardiovascular mortality. A few studies have 
directly compared uric acid with hs-CRP26 and have proved a positive 
correlation between the two markers. Uric acid is basically an antioxidant which 
turns into a prooxidant under certain circumstances. 
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BIOCHEMISTRY OF URIC ACID 
 Uric Acid (2,6,8- trioxypurine- C5H4N4O3) is a weak organic acid that is 
endogenously produced  by purine metabolism6. It is formed by the liver and 
mainly excreted by the kidneys and intestines.   RNA and DNA are degraded 
into purine nucleotides and bases, which are metabolized by the enzyme 
Xanthine Oxidoreductase into xanthine and uric acid. These steps are 
irreversible and produce superoxide anions. In lower animals, uric acid is 
converted to a water soluble product, allantoin by the enzyme uricase and 
excreted in urine. Man is the only mammal lacking the enzyme uricase6 (with 
the exception of the Dalmatian dog), thus having higher levels of uric acid in 
blood. Nearly two thirds of serum uric acid is produced endogenously while one 
third is produced from break down of purines. Approximately 70% of urate 
produced daily is excreted by the kidneys. In the kidney, uric acid is filtered, 
reabsorbed or excreted by the proximal tubules by the urate/anion exchanger6, 
URAT 1.  URAT 1 has been identified over brush border membranes of 
proximal tubular cells and is inhibited by the angiotensin II receptor blocker, 
Losartan6. 
 Normally men have higher uric acid levels when compared to females. 
Upper limit of normal uric acid levels in men is 5.5 mg/dl17 while in women, it 
is 4.5 mg/dl17. Uric acid levels increase with age. Pre menopausal women have 
lower uric acid levels than post menopausal women as estrogen has a uricosuric 
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effect. Post menopausal females have similar urate levels as that of men. 
Alcohol causes hyperuricemia through increased lactate production, that 
competes with uric acid for the URAT transporter52. Diuretics lead to volume 
depletion and decreased absorption of uric acid7. 
 
OXIDATIVE STRESS & XOR 
 Reactive oxygen species(ROS) are  normal  byproducts of aerobic 
metabolism. In the heart, the potential sources of ROS include xanthine oxidase 
and NADPH oxidase. According to recent studies, Xanthine oxidase plays a 
more significant role in the production of ROS  when compared to NADPH 
oxidase.  ROS produced by XOR  can modulate the activity of various 
intracellular proteins and signalling pathways including proteins involved in 
excitation-contraction coupling, such as sarcoplasmic reticulum calcium release 
channels, ion channels, myofilament proteins and signalling pathways which are 
coupled to myocyte  growth. The modulation of activity of ryanodine receptors 
and Ca-ATPase result in decreased cardiac contractility. Oxidative stress occurs 
when production of ROS exceeds the buffering activity of anti-oxidant defence 
systems, leading to excess of ROS within the cell. ROS may arise secondary to 
mechanical strain of the myocardium, neurohormonal stimulation or due to 
inflammatory cytokines.   
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INJURIOUS STIMULI RESPONSIBLE FOR XANTHINE OXIDASE 
ACTIVATION AND OXIDATIVE STRESS7(TABLE 4) 
• Angiotensin II 
• Amylin 
• Advanced glycosylation   
/fructosylation end products 
• Apolipoprotein B 
• Anti oxidant reserve 
compromised 
• Aging 
• Asymmetrical dimethyl arginine 
• Free fatty acid toxicity 
• Lipotoxicity- Hyperlipidemia 
 
• Insulin toxicity 
• Inflammation 
• Glucotoxicity 
• Sorbitol/ Poliyol pathway 
• Pseudohypoxia( increased 
NADH/NAD ratio) 
• Hypertension  
• Homocysteine 
• Hs-CRP 
• Triglyceride toxicity 
• Uric Acid toxicity – conditional 
pro oxidant        
 
XANTHINE OXIDOREDUCTASE 
 Xanthine oxidoreductase (XOR) belongs to the group of molybdenum 
iron-sulfur-flavin hydroxylase group of enzymes. It is predominantly found in 
liver, GIT, kidneys, brain and mammary gland16.  It is also found throughout the 
cardiovascular system and endothelium bound forms have been described. But 
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these are 10 to 1000 times lower than the levels found in liver and mammary 
gland. Expression of these forms are increased in the presence of ischaemia16 
and when there is an increase in pro inflammatory cytokines.                  
 The subcellular location XOR remains controversial till now. In the past, 
XOR was thought to be entirely cytosolic but researches have shown XOR 
expression in the rough endoplasmic reticulum, lysosomes and peroxisomes of 
hepatocytes and in Kupffer and sinusoidal cells 
 There is about three fold difference in the expression of Xanthine 
Oxidase activity among individuals. This is due to  the presence of various 
inactive forms like desulfo-XOR.   XOR has two interconvertible forms, 
xanthine oxidase and xanthine dehydrogenase. The major role of xanthine 
oxidase is conversion of xanthine and hypoxanthine to uric acid.  Xanthine 
dehydrogenase converts NAD+ to NADH. These actions yield hydroxyl free 
radicals and hydrogen peroxide. 
XANTHINE OXIDASE 
Hypoxanthine+ H2O+ 2O2                      Xanthine+ O2- +H2O2 
Xanthine+ H2O2+ 2O2                             Uric acid+ O2-+ H2O2 
XANTHINE DEHYDROGENASE 
Hypoxanthine+ NAD+ +H2O                   Xanthine+ NADH+  H+ 
Xanthine+ NAD+ +H2O                            Uric acid+ NADH+  H+ 
 
TABLE5 
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XDH prefers NAD+ as oxidising substrate but is able to react with O2 ,while 
XO uses only O2( Daria Pasalik et al)52 
FACTORS THAT REGULATE  XOR GENE EXPRESSION(TABLE 6) 
POSITIVE REGULATION NEGATIVE REGULATION 
Hypoxia 
Interferon gamma 
Lipopolysaccharide 
Interleukin-1 
Interleukin-6 
Dexamethasone 
Tumor necrosis factor alfa 
Prolactin 
Cortisol 
Hyperoxia 
 
 
 Oxygen tension regulates XOR gene expression and also affects the post 
translational modification of proteins. Studies have shown that xanthine oxidase 
expression in bovine endothelial cells doubles after exposure to prolonged 
hypoxia16. It has been proposed that hypoxia causes phosphorylation of the 
enzyme, which increases the enzymatic activity if xanthine oxidase. 
 The other prime factor that influences XOR expression is nitric oxide 
levels in the endothelium. Nitric oxide inhibits the expression of XOR 
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directly16. Xanthine Oxidoreductase levels are brought down by the reduction of 
nitrates into nitrites.  
 Studies show that xanthine oxidase levels are higher in heart failure and 
in the recent days has been gaining importance over NADPH oxidase as a 
source of oxidative stress in these conditions35. Xanthine oxidase has also been 
implicated in intermittent hypoxia induced vascular dysfunction.    It has also 
become an area of therapeutic target.       
 
CAUSES OF HYPERURICEMIA      
 Under steady state conditions, uric acid production is in balance to its 
disposal. High levels of uric acid are seen in conditions associated with high cell 
turn over, enzymatic defects or impaired excretion. Hyperuricemia is a state in 
which uric acid levels exceed the urate solubility.  Uric acid in the blood is 
saturated at 6.4-6.8 mg/dl at ambient conditions, with the upper limit of 
solubility placed at 7 mg/dl17. In men, hyperuricemia is defined as uric acid 
level >7 mg% in males, while in females it is > 6 mg%6. In children, 
hyperuricemia is defined as uric acid levels more than 5 mg%. 
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CAUSES OF HYPERURICEMIA(TABLE 7) 
 
Genetic Causes 
 
     Familial Hyperuricemic Nephropathy 
 
     Lesch-Nehan Syndrome   (HGPRT mutation)   
 
     Phospho ribosyl pyrophosphate synthase (PRPPS)mutation 
 
 
Drugs 
 
     Thiazides  
 
      Loop diuretics 
 
      Calcineurin Inhibitors(Cyclosporine>Tacrolimus) 
 
      Pyrazinamide 
 
      Low dose Aspirin 
 
Dietary Causes 
 
     Diet high in purines(shell fish,organ meats,fatty meats) 
 
     Diet high in fructose(high fructose corn sugar, table sugar,honey) 
 
     Ethanol  
 
 
Volume depletion 
 
Hypoxia(tissue or systemic) 
 
Increased cell turn over 
 
myeloproliferative disorders, polycythemia vera 
 
Conditions associated with higher uric acid levels 
 
        Renal failure 
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        Metabolic syndrome/Obesity 
 
        Untreated hypertension 
 
        African American race 
 
        Pre eclampsia 
 
        Vigorous exercise 
      
                   
Reference:Becker et al. 2005 
 Long standing hyperuricemia leads to pathological damage to kidney, 
joints and connective tissue. Hyperuricemia without associated complications is 
called asymptomatic hyperuricemia. Recent studies have revealed that 
asymptomatic hyperuricemia is associated with hypertension, metabolic 
syndrome, dyslipidemia and cardiovascular disease.  
 
BIOLOGICAL ROLES OF URIC ACID 
 As said earlier, uric acid levels are higher in humans when compared to 
other mammals. It has been proposed that this confers a survival advantage to 
humans as increased uric acid levels maintain normal blood pressure in the 
presence of low salt intake (Watanabe et al).  Due to its double bond, uric acid 
has great anti-oxidant activity and is responsible for more than 2/3 of plasma 
anti-oxidant activity18. This survival advantage has also been linked to the 
prevention of ageing due to free radical formation (Ames et al). It seems uric 
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acid and xanthine oxidoreductase may have vast biological roles apart from 
purine metabolism. Hancock et al has proposed that XOR has anti microbial  
properties  through Nitric oxide dependent mechanism. Breast milk has a high 
XOR activity which prevents the occurrence of gastroenteritis.  
 The well established correlation between uric acid levels and 
atherosclerosis could be a protective reaction (anti-oxidant) or a primary cause 
(pro-oxidant). This might be due to uric acid  being activated against oxidative 
stress but behaving as a pro oxidant when produced in excess well above 
normal limits. 
 Conversely, uric acid may be an indirect evidence of high levels of 
xanthine oxidase which produces reactive oxygen species. Many hold to the 
simple concept that serum uric acid in patients with metabolic syndrome, 
hypertension, type 2 DM, renal failure may reflect a compensatory mechanism 
to the oxidative stress. However, this does not explain why hyperuricemia is 
associated with worse outcomes. Some authors have proposed the concept of an 
anti-oxidant prooxidant switch or urate redox shuttle depending upon the local 
milieu in the atherosclerotic plaque.7 
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THE ANTI OXIDANT PROOXIDANT URATE REDOX SHUTTLE7           
 Serum uric acid is an important anti oxidant during the early stages of 
atherosclerosis and is a major determinant of plasma anti oxidative capacity. 
However, when the levels reach the upper one-third of the normal limits, it 
becomes pro oxidant. This is known as the anti oxidant prooxidant urate redox 
shuttle. This anti-oxidant pro oxidant shuttle seems to depend on its surrounding 
environment such as timing (early or late in disease process), the surrounding 
oxidant milieu , location of substrate, acidity,  the  duration of supply of oxidant 
substrates and the depletion of anti  oxidants. In the atherosclerotic vulnerable 
plaque, the intima of the vessel has an acidic medium, is depleted of local anti 
oxidants, and associated with decrease in e NOS production. e NO is a naturally 
occurring anti –oxidant in the blood vessel. In atherosclerosis, there is decrease 
in the production of e NO and there is uncoupling of eNOS7. This leads to 
vascular dysfunction. This is also one of the proposed mechanisms for diabetic 
microvascular complications. 
 All these processes lead to increased production of purines due to 
apoptosis and necrosis of the vascular endothelial and smooth muscle cells, 
thereby increasing uric acid synthesis , allowing it to undergo a prooxidant anti 
oxidant shuttle.     
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PROOXIDANT ANTI OXIDANT URATE  REDOX SHUTTLE IN AN 
ATHEROSCLEROTIC PLAQUE(FIGURE 1) 
NECROSIS OF VASCULAR ENDOTHELIUM 
PRESENCE OF ANTI INFLAMMATORY CELLS IN ATHEROSCLEROTIC 
PLAQUE 
 
   DNA RNA DEGRADATION 
                                                   ENDOTHELIAL DYSFUNCTION 
         ADENINE, GUANINE 
                                                ENOS UNCOUPLING         INCREASEDLDLc 
          XANTHINE                          
                                                 REDUCED ANTIOXIDANTS                              
                                                                                      XOR                          
ANTI OXIDANT URIC ACID                              PROOXIDANT URICACID                      
                                                                              
                                            O 2                         H2O2          
REACTIVE   OXYGEN   SPECIES 
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OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION 
 Oxidative stress contributes significantly to endothelial dysfunction in 
cardiovascular disease as superoxide radicals readily inactivate nitric oxide 
which is a potent vasodilator. Nitric oxide and superoxide radicals react at a rate 
three fold greater rate than the rate at which superoxide dismutase clears O2-
(Cai &Harrison) 
 Endothelium bound XOR inhibits nitric oxide dependent cyclic GMP 
production in smooth muscle cells thereby impairing vasodilatation(Houston et 
al.) The role of XOR in oxidative stress and endothelial dysfunction has been  
confirmed by the isolation of XOR from diseased coronary arteries . It exhibits 
a negative correlation with endothelium mediated vasodilatation(Landmesser et 
al. 2002). Local uric acid concentrations are elevated to five to six fold higher in 
atherosclerotic plaques indicating upregulation of XOR activity16(Patetsios et al. 
2001) 
 
URIC ACID IN METABOLIC SYNDROME 
 Higher uric acid levels are seen in people with metabolic syndrome. This 
is thought to be due to the increased production of fatty acyl   co A in tissues23. 
This results in the formation of AMP, which breaks down into adenine and then 
into uric acid.   Higher intake of fructose has been implicated in the 
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pathogenesis of metabolic syndrome. This is because fructose enters the cells, 
especially hepatocytes and triggers the uninhibited use of  ATP for its 
metabolism by fructokinase. ATP depletion results in lactic acidosis and 
resultant hyperuricemia52. Due to the excessive use of ATP, synthetic processes 
are triggered, especially triglyceride levels are raised23. Studies have shown that 
measures that decrease triglyceride levels are associated with decrease in uric 
acid levels.  Hyperinsulinemia reduces the excretion of uric acid and thereby 
induces hyperuricemia in metabolic syndrome52. 
 
SERUM URIC ACID LEVELS IN HYPERTENSION 
 Disturbances in renal function is one of the major mechanisms involved 
in the pathogenesis of systemic hypertension. Any disturbance in the function of 
URAT transporters, polymorphisms of genes associated with these transporters 
and reduced glomerular filtration rate are the main causes of hyperuricemia in 
hypertension23. It has also been postulated that uric acid causes tubulointerstitial 
disease of the kidneys in hypertensive patients leading to salt dependent 
hypertension23. Hypertension also induces microvascular renal injury and causes 
an increase in lactate levels, which in turn leads to hyperuricemia52. In essential 
hypertension, there is alteration of renal handling of sodium, leading to increase 
in mean arterial pressure and decrease in renal blood flow, thus leading to 
decreased excretion of uric acid.  
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URIC ACID AND DYSLIPIDEMIA 
 Higher uric acid levels have been observed in persons with high waist hip 
ratio. In these subjects uric acid levels show a linear correlation with the plasma 
levels of leptin produced by the adipose tissue. Triglyceride levels have a 
significant association with hyperuricemia. This is because Triglyceride 
synthesis in the liver is associated with increased requirement of NADPH and it 
also accelerates purine formation, leading to hyperuricemia23. Some studies 
show a negative correlation of uric acid with HDL. 
URIC ACID AND CARDIAC DISEASE 
 Uric acid first gained medical importance when it was discovered by 
Garrod as the cause of gout. About 50% of patients with gout had hypertension, 
one quarter suffered from renal disease, and majority developed cardiovascular 
disease. Subsequent researches proved its association with hypertension, 
atherosclerosis, renal disease and stroke. 
 In 1951, Gertler et al proved that uric acid levels are much higher in 
hospitalised CAD patients when compared to patients hospitalised due to other 
diseases17. Uric acid has also been identified as a risk factor in the recent past. It 
has been found that uric acid increases platelet aggregation, reduces nitric oxide 
production and causes endothelial dysfunction, raises the levels of oxidised 
LDL and promotes atherosclerosis37.  But the fact whether uric acid is a 
causative factor or just a risk marker remains unknown.  
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 One particular study has proved that uric acid levels along with left 
ventricular mass estimation is a strong predictor of future cardiovascular events 
like angina, myocardial infarction, congestive cardiac failure and even 
cerebrovascular event. In a study conducted in China, Chang-Fu Kuo et al have 
brought out association of hyperuricemia with increase in arterial stiffness and 
the development of cardiac hypertrophy14.  
 Uric acid levels show a linear correlation with cardiovascular mortality in 
patients with heart failure. This has been linked to endothelial dysfunction and 
mechanoenergetic uncoupling ( increase in energy consumption while cardiac 
work decreases), which lead to increased formation of lactate. Lactate competes 
with uric acid for the URAT transporter and hence leads to hyperuricemia. 
Patients with heart failure have very low levels of Superoxide dismutase ,while 
the XOR acttivity is enhanced to >200% in the endothelium. Allopurinol has 
been proved to increase myocardial contractility and decrease the demand of the 
stunned myocardium in animal studies. 
 Hyperuricemia has also been linked to ischaemia-reperfusion injury that 
occurs in myocardial infarction16. Though the precise mechanisms have not 
been determined yet, the increase in substrates for the enzyme XOR during 
ischaemia appears to positively regulate XOR expression. XOR levels are found 
to be eight times elevated in aortic endothelium after reperfusion following 
ischaemia.    
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MAJOR STUDIES THAT STUDIED ASSOCIATION OF URIC ACID 
WITH CARDIOVASCULAR OUTCOMES (TABLE 8) 
SLNO STUDY                      RESULTS 
1 
THE NHANES I 
EPIDEMIOLOGIC 
FOLLOW UP STUDY 
Serum uric acid levels predicted cardiovascular 
mortality in both males and females even after 
adjustment for age and race and this association 
was well pronounced in post menopausal females
2 THE FRAMINGHAM STUDY 
A prospective study conducted on whites which 
proved no significant association between uric 
acid levels and cardiovascular mortality when 
adjustments were made for age, race and other 
covariates 
3 THE LIFE STUDY 
Serum uric acid levels had significant association 
with incidence of cardiovascular events in high 
risk hypertensive subjects 
4 THE PIUMA STUDY 
Serum uric acid levels in highest quartiles were 
associated with higher incidence of fatal 
cardiovascular events and all cause mortality 
5 KOJIMA ET AL 
A metaanalysis of nine prospective studies in 
patients with acute myocardial infarction that 
found a significant association between uric acid 
levels with age, Killip  class and cardiovascular 
mortality 
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STUDIES OF URIC ACID IN CARDIOVASCULAR DISEASE AND 
OUTCOMES 
 There are two large studies regarding the role of uric acid in 
cardiovascular disease and outcomes. 
THE NHANES 1 EPIDEMIOLOGIC FOLLOW UP STUDY44 
 The NHANES 1 Epidemiologic Follow up Study( 1971-1987) indicated 
that baseline serum uric acid was an independent predictor of mortality, 
particularly of cardiovascular  death, but only in women. But another large cross 
sectional study, the Framingham’s Study reported that the apparent relationship 
of uric acid to cardiovascular mortality was not sustained. The authors 
concluded that the use of diuretics reduced the statistical significance of serum 
uric acid to cardiovascular outcome. So in order to prove the unresolved 
correlation between uric acid levels and cardiovascular mortality, the NHANES 
I epidemiologic follow up study was extended to a period of five years from 
1987 to 1992. This nearly doubled the deaths available for study in the sampled 
population. 
 The total NHANES 1 sample included 20729 persons, aged 25 to 74 
years. Low income persons, women of child bearing age, the elderly were 
oversampled. Subjects were excluded if they had myocardial infarction , gout, 
stroke, or were pregnant at the baseline. Of the total sample, a subsample of 
6913 subjects called the detailed sample was analysed in greater depth. Follow 
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up data was collected in four  series of follow up.  Death was analysed for all 
causes and ischaemic heart disease.   
 Of the total deaths, 45.9% were due to cardiovascular disease. It was 
observed that uric acid levels predicted the cardiovascular mortality of both men 
and women older than 45 years of age whereas it did not predict the outcome in 
younger individuals. In menopausal women, the predictive value of uric acid 
remained significant even when it was adjusted for post menopausal status. 
Subjects who were on diuretics and alcoholics( consuming alcohol more than 
twice per week)  had higher uric acid levels when compared to others. In 
women using diuretics, the risk of cardiovascular mortality for a similar 
increase in uric acid level was higher when compared to those not on diuretics. 
In men with cardiovascular risk factors and those on diuretics, no significant 
association was obtained between uric acid levels and cardiovascular mortality. 
Even in persons with no traditional risk factors, high uric acid levels predicted 
mortality. These results were similar to that obtained in a previous NHANES 
study that was extended into this study.    
THE FRAMINGHAM’S STUDY39 
 The total population included in the study was 6763 . Similar to the 
previous study, risk factors were noted and the subjects were followed up for 23 
years. The total deaths were 1560 and cardiovascular deaths were 617.  The uric 
acid levels were higher in all age groups of men when compared to women. 
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Among men, high serum uric acid was associated with decreased mortality. 
This study found no significant correlation between serum uric acid levels and 
cardiovascular mortality or incidence of cardiovascular events after adjusting 
for age, diuretic use , diabetes and other factors. Higher uric acid levels were 
significantly associated with diuretic use. But the limitation of this study was 
that it studied majority of white people. This result cannot be extrapolated to 
other population. The socioeconomic groups were not taken into consideration.  
 
NHANES vs FRAMINGHAM’S STUDY 
 As mentioned previously, the study population was heterogenous in 
NHANES study, while it contained predominantly whites in the Framingham’s 
study. The mean age group was higher in the NHANES study and increasing 
age was one of the determining factors of cardiovascular mortality.  NHANES 
showed a significant correlation of uric acid with cardiovascular mortality even 
in the whites.  
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STUDIES THAT ASSESSED URIC ACID LEVELS IN ACUTE 
CORONARY SYNDROMES 
 Vladimir Trkulja8 et al has performed a meta analysis of nine studies 
conducted in patients with acute myocardial infarction and has proved the 
association of uric acid levels with cardiovascular mortality. Out of the nine 
studies, six were conducted in patients with STEMI who underwent PCI and 
three in mixed population of acute myocardial infarction. The outcomes studied 
were mortality and occurrence of major adverse cardiac events. Short term (upto 
30 days) and medium /long term outcomes were studied. There was a 
significant association between higher uric acid levels and major adverse 
cardiac events and short and medium/long term mortality. 
 The limitation of this study was that some studies were retrospective. No 
study matched the normouricemic and hyperuricemic subjects with respect to 
age, Killip class, or renal function. Age > 65 years, Killip class>II/III and renal 
insufficiency were the most important predictors of mortality in acute 
myocardial infarction. Uric acid levels significantly correlated with these 
factors.  
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MATERIALS AND METHODS 
STUDY DESIGN 
 This is a prospective study conducted on a sample South Indian 
population admitted in the department of Cardiology during the period of 2011 
to 2012. The study included a standardized questionnaire and examination, 
based on  which patients were included in the study. A total of 152 subjects 
admitted with ST elevation Myocardial Infarction were analysed and among 
them, patients with evolved MI, prior history of myocardial infarction, renal 
disease, and those on diuretics and aspirin, were excluded. The total sample 
population included in the study was 75 patients, aged 24 to 75 years.   The 
study population included 65 males and 10 females.  
 
INCLUSION CRITERIA 
 1. Acute ST elevation MI, defined as 
 Classical anginal pain within the prior 12 hours associated with either 
A) STsegment elevation in atleast two contiguous leads, greater than 0.1 mV in 
limb leads or greater than 0.2 mV in precordial leads  
B)New or presumably new left bundle branch block. 
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EXCLUSION CRITERIA 
1. Patients with chronic kidney disease 
2. Evolved MI 
3. Patients with contraindications to thrombolysis 
4. Prior history of coronary artery disease 
5. Chronic alcohol intake/ Binge drinking in the past one week. 
6. History of aspirin/ diuretic intake 
7. Patients on Anti Tuberculosis Treatment 
8. Gout 
9. Presence of myeloproliferative diseases 
10. Pregnancy  
11. Hypothyroidism  
12. Patients on calcineurin inhibitors. 
 
METHODS 
    A detailed history was elicited regarding duration of chest pain, nature of 
chest pain, associated symptoms, previous illness and medications, presence of 
risk factors like diabetes, hypertension, smoking, alcoholism, family history of 
MI , and a detailed clinical examination was done and patients were categorised 
into Killip class I to IV. The window period was noted and patients with acute 
MI and a window period of less than 12 hrs were thrombolysed with 
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streptokinase 1.5 million units. Any complication occurring during thrombolysis 
was made note of. Continuous cardiac monitoring was done for all patients 
atleast during the initial three days and prolonged if complications occurred. 
 On admission, routine investigations like blood sugar , urea, creatinine, 
complete blood count were done and serum uric acid level was estimated. Total 
cholesterol and triglyceride level was also estimated on the day of admission. 
Fasting and post prandial blood sugar was estimated in all patients. Diabetes 
was defined as fasting blood sugar >126 mg% or post prandial blood sugar>200 
mg% or euglycemia with the use of  insulin or oral hypoglycemic agents. Body 
mass index was calculated as weight in kg/ height in m2 and TIMI risk score for 
STEMI was calculated for all patients on admission (table 4).  
 Serum uric acid level was reestimated on day three. Echocardiography 
was done on the fifth day and ejection fraction was assessed.  Patients were 
followed up till their discharge or till one week whichever was longer. Any 
complications or mortality occurring during this period were also noted. 
Adverse cardiac events included arrhythmias (excluding benign premature beats 
and Idioventricular rhythm occuring during thrombolysis), sudden cardiac 
arrest, shock, cardiac failure, ventricular septal rupture, papillary muscle 
dysfunction, free wall rupture, reinfarction and pericarditis. Other complications 
like bleeding episodes, cerebrovascular accident and acute kidney injury were 
also taken into account.  
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STATISTICAL ANALYSIS 
 Data analysis was done and subjects were divided into two groups: one 
group had patients with normal uric acid levels and the other had patients with 
hyperuricemia. Serum uric acid levels  between the two groups on day one was 
compared by Students unpaired ‘t’ test and within the groups on days one and 
three was compared  by paired ‘t’ test. The continous variables like age, 
window period, lipid profile, BMI, TIMI score were compared by  unpaired ‘t’ 
test. The categorical variables like sex, Killip class, diabetes, hypertension, 
smoking , lipid profile, complications and mortality were compared between the 
two groups by χ2 (Chi-square) test, Odd’s ratio and Z test of proportions 
wherever applicable. The statistical package IBM SPSS statistics -20 was 
utilized for analysis and interpretations. The P- values less than 0.05 (P<0.05) 
were considered as significant in two tailed condition. 
 
 
 
 
 
 
 
48 
 
RESULTS AND OBSERVATIONS 
               The study population had 75 subjects in the age group of 21 to 80 
years. The mean age of the total population was 56.80 years. 
AGE DISTRIBUTION IN STUDY POPULATION 
TABLE 9 
AGE 21-30 31-40 41-50 51-60 61-70 71-80 
MALE 2 5 7 26 17 5 
FEMALE 0 1 1 3 8 0 
           
SUA IN 
mg/dL 
AGE IN YEARS 
21-30 31-40 41-50 51-60 61-70 71-80 
3.1-5.0 0 5 2 6 0 0 
5.1-7.0 2 1 5 12 10 1 
7.1-9.0 0 0 1 11 10 4 
>9.0 0 0 0 0 2 3 
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FIGURE 2:The mean age of the total population was 56.80 years. Men had a 
mean age of 57.55 years and the mean age in women was 66.04 years. 
 
MEAN URIC ACID LEVEL IN DIFFERENT AGE GROUPS (TABLE 10) 
AGE 21-30 31-40 41-50 51-60 61-70 71-80 
MALE 5.9 4.58 5.8 6.28 7.86 8.24 
FEMALE - 4.2 5.2 5.7 6.48 - 
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FIGURE 3 
 
FIGURE 4: Uric acid levels increased with age in both males and females 
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Comparison of Hyperuricemia and Non-Hyperuricemia cases according to 
age  (Table 11) 
                
Variables 
Hyperuricemia Non- Hyperuricemia
Difference
B/W H 
& NH 
‘t’ df Sig. 
Mean SD Mean SD 
Age 
(years) 64.2 7.2 50.8 10.9 13.4 6.297 73 P<0.001 
                      
Age differed significantly between the two groups(p<0.05). Uric acid levels 
were higher in older individuals.       
SEX DISTRIBUTION  
SEX  DISTRIBUTION
MALE
FEMALE
   FIGURE:5:     The studied population had 87% males and 13% females. 
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 PREVALENCE OF HYPERURICEMIA IN THE STUDY POPULATION  
(TABLE 12) 
SEX NORMAL URIC ACID HYPERURICEMIA 
MALE 32 33 
FEMALE 4 6 
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FIGURE 6: The prevalence of hyperuricemia was 50.77% in men and 60% in 
women.  
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DISTRIBUTION OF  URIC ACID LEVELS IN MALES AND FEMALES  
( TABLE 13) 
 
 
SEX 
SERUM URIC ACID IN mg/dl 
3.1-5.0 5.1-7.0 7.1-9.0 >9.1 
MALE 12 23 25 5 
FEMALE 1 8 1 - 
 
 
 
FIGURE 7:   Mean uric acid level in the studied population was 6.31mg%.  
Men had relatively higher uric acid levels when compared to females.(mean – 
6.74 mg%) 
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FIGURE 8: The mean uric acid level in females was 5.49 mg% 
 
Table-14. Association between serum uric acid and gender 
Genders 
 
Acute STEMI Sr uric acid 
χ2 df Sig. 
Hyper Non Hyper Total
Male 33 32 65 
0.296 1 P>0.05 Female 6 4 10 
Total 39 36 75 
 
 The Table 14 shows the association between serum uric acid with genders 
of STEMI. The gender did not have any significant association with Sr. Uric 
Acid (P>0.05). 
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TYPE OF MI DISTRIBUTION IN STUDY POPULATION 
TABLE 15 
SEX 
TYPE OF MYOCARDIAL INFARCTION 
AWMI ASMI IWMI LBBB 
MALE 29 14 19 3 
FEMALE 1 3 6 0 
 
0 5 10 15 20 25 30
AWMI
ASMI
IWMI
LBBB
NO OF SUBJECTS
T
Y
PE
 O
F 
M
I
DISTRIBUTION OF TYPE OF MI
FEMALE
MALE
FIGURE 9: Anterior wall MI was the commonest encountered type in the 
studied population. 
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FIGURE 10:  Majority of the males suffered anterior wall infarction. 
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FIGURE 11:  Inferior wall MI was the commonest presentation among females. 
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DISTRIBUTION OF TYPES OF MYOCARDIAL INFARCTION IN 
DIFFERENT URIC ACID QUARTILES(TABLE 16) 
TYPE OF MI 
SERUM URIC ACID IN mg/dl 
3.1- 5.0 5.1 – 7.0 7.1 – 9.0 >9.0 
AWMI 0 10 17 3 
ASMI 3 12 2 1 
IWMI 11 10 5 0 
LBBB 0 0 2 1 
 
 
FIGURE 12 
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FIGURE 13: Anterior wall MI and LBBB pattern were associated with higher 
uric acid quartiles while inferior wall MI was associated with lower uric acid 
quartiles. 
Table-17. Association between  Serum uric acid and Type of STEMI. 
Type 
Acute STEMI Sr uric acid 
χ2 df Sig. 
Hyper Non Hyper Total 
AS 7 10 17 
23.247 1 P<0.01 
AW 22 8 30 
IW 2 13 15 
IWPW 2 3 5 
IWRVPW 3 0 3 
IWRV 0 1 1 
LBBB 3 0 3 
LWRW 0 1 1 
Total 39 36 75 
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  Table 17 shows the relation between type of STEMI with Uric acid. 
Anterior wall MI was associated with  Hyperuricemia and Inferior wall MI was 
associated with Non Hyperuricemia (P<0.01).  
DISTRIBUTION OF KILLIP CLASS AMONG STUDY POPULATION 
(TABLE 18) 
KILLIP I II III IV 
MALE 35 17 7 6 
FEMALE 8 1 1 0 
TOTAL 43 16 8 6 
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FIGURE 14: Majority of the subjects were in Killip class I . 
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FIGURE 15: 80% of females presented with Killip class 1. Higher Killip classes 
occurred commonly in men. 
 
COMPARISON OF URIC ACID LEVELS WITH KILLIP CLASS 
(TABLE 19) 
 
KILLIP 
CLASS 
SERUM URIC ACID IN mg/dl 
3.1-5.0 5.1-7.0 7.1-9.0 >9.0 
KILLIP I 13 25 4 1 
KILLIP II 0 5 12 1 
KILLIP III 0 0 5 2 
KILLIP IV 0 0 5 1 
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FIGURE:16  : Higher Killip Classes were associated with higher uric acid levels 
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FIGURE:17 : Mean uric acid levels were higher in Killip class III and IV 
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Table-20. Association between  Sr uric acid and Killip class. 
Killip 
class 
Acute STEMI Sr uric acid 
χ2 Df Sig. 
Hyper Non Hyper Total 
I 10 33 43 
33.625 3 P<0.001 
II 16 2 18 
III 7 1 8 
IV 6 0 6 
Total 39 36 75 
  Table 20 shows the association between serum uric acid and  Killip class.  
Killip class III and IV were strongly associated with Hyperuricemia. (P<0.001). 
 
 
CORRELATION BETWEEN TIMI SCORE AND URIC ACID LEVEL 
(TABLE 21) 
MEAN 
SUA IN 
mg/dl 
 TIMI RISK SCORE 
0 1 2 3 4 5 6 7 8 9 12 
IN MEN 4.4 4.75 5.62 6.7 7.11 7.72 7.2 8 8.15 8.7 8.8 
IN 
WOMEN 4.2 4.7 5.85 6.2 6.2 - - 6.9 - - - 
 
 
63 
 
4.47 4.75
5.62
6.7
7.11
7.72
7.2
8 8.15
8.7 8.8
0
1
2
3
4
5
6
7
8
9
10
0 1 2 3 4 5 6 7 8 9 12
U
RI
C 
A
CI
D
 IN
 m
g/
dl
TIMI SCORE
TIMI SCORE VS URIC ACID IN MEN
UA
 
FIGURE 18: Uric acid levels increased with age in males. 
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FIGURE 19: Uric acid levels increased with increase in TIMI risk score  in both     
male and female populations. 
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Comparison of Hyperuricemia and Non-Hyperuricemia cases based on 
TIMI score (Table 22) 
                
Variables Hyperuricemia 
Non- 
Hyperuricemia
Difference
B/W H 
& NH 
‘t’ df Sig. 
Mean SD Mean SD 
TIMI 6.5 2.1 1.7 1.4 4.8 11.610 73 P<0.001
  
TIMI score differed significantly between the two groups(P<0.001). 
 
DISTRIBUTION OF URIC ACID LEVELS IN DIABETICS AND NON-
DIABETICS (TABLE 23) 
GLYCEMIC 
STATUS 
SERUM URIC ACID IN mg/dl 
QUARTILE1 
3.1-5.0   
QUARTILE2
5.1-7.0 
QUARTILE3 
7.1-9.0 
QUARTILE4
>9.0 
DIABETICS 3 10 14 2 
NON 
DIABETICS 10 21 12 2 
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PERCENTAGE OF DIABETICS IN STUDY 
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FIGURE 20:  39% of the total population had Diabetes 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
DIABETICS NON DIABETICS
DISTRRIBUTION OF URIC ACID LEVELS IN 
DIABETICS AND NON DIABETICS
QUARTILE 4
QUARTILE 3
QUARTILE 2
QUARTILE 1
 
FIGURE 21: Diabetics had higher uric acid levels when compared to non 
diabetics. 
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COMPARISON OF URIC ACID LEVELS IN NORMOTENSIVES AND 
HYPERTENSIVES( TABLE 25) 
 
SERUM URIC ACID (in mg/dl) 
QUARTILE1 
3.1-5.0 
QUARTILE2 
5.1-7.0 
QUARTILE3 
7.1-9.0 
QUARTILE 4 
>9.0 
NORMOTENSIVES 12 23 11 2 
HYPERTENSIVES 1 8 15 3 
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FIGURE 22: The presence of hypertension was associated with higher uric acid 
levels. 
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Table-26. Association of  Serum uric acid with Diabetes and Hypertension 
Risk 
Factors 
Acute STEMI Sr uric acid 
χ2 df Sig. 
Hyper Non Hyper Total
Diabetic 11 8 19 
15.562 3 P<0.001 
Hyperten 11 5 16 
DM+HT 9 1 10 
NIL 8 22 30 
Total 39 36 75 
 
The Risk Factors such as Diabetes, Hypertension and DM+HT were associated 
with Hyperuricemia and the absence of these risk factors was associated with 
Non- Hyperuricemia (P<0.001). 
 
 
COMPARISON OF URIC ACID IN SMOKERS AND NON SMOKERS 
( TABLE 27) 
 
SERUM URIC ACID IN mg/dl 
QUARTILE1  
3.1-5.0 
QUARTILE2 
5.1-7.0 
QUARTILE3 
7.1-9.0 
QUARTILE4 
>9.0 
SMOKERS 6 14 12 5 
NON 
SMOKERS 6 8 13 0 
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FIGURE 23: The distribution of uric acid levels were similar in smokers and 
non smokers.  
 
 
Table-28. Association between serum uric acid with smoking habit 
 
Smoking 
Acute STEMI Sr uric acid 
χ2 df Sig. 
Hyper Non Hyper Total 
Yes 18 19 37 
0.329 1 P>0.05 No 21 17 38 
Total 39 36 75 
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Table 28 shows the association between serum uric acid with smoking . 
Smoking did not have any significant association with Sr. Uric Acid (P>0.05). 
 
CORRELATION OF MEAN URIC ACID WITH NUMBER OF RISK 
FACTORS  (TABLE 29) 
MEAN URIC 
ACID IN mg/dl 
NO OF RISK FACTORS 
0 1 2 3 4 
IN MALES 5.2 6.42 7.11 8.2 8.75 
IN FEMALES 6.08 6.15 5.5 5.2 - 
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FIGURE 24: The presence of diabetes, hypertension, smoking, family history of 
CAD was compared with uric acid level. Uric acid level increases with number 
of risk factors. This positive correlation is not seen in female population. 
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COMPARISON OF TRIGLYCERIDE LEVEL WITH URIC ACID 
(TABLE 30) 
TRIGLYCERIDE 
in mg/dl 
 URIC ACID LEVELS IN mg/dl 
 3.1-5.0  5.1-7.0 7.1-9.0   >9.0  
50-150 11 15 9 0 
151-300 2 14 14 5 
>300 0 2 3 0 
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FIGURE 25: Uric acid  increased with increase in triglyceride level 
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Table 31. Comparison of Hyperuricemia and Non-Hyperuricemia cases 
based on Triglyceride levels 
                
Variables 
Hyperuricemia Non- Hyperuricemia DifferenceB/W H 
& NH 
‘t’ df Sig. 
Mean SD Mean SD 
TGL 171.1 46.9 144.4 36.2 26.7 2.741 73 P<0.01 
 
Triglyceride levels  differed significantly between the two groups(P<0.01).  
 
COMPARISON OF URIC ACID LEVEL WITH SERUM TOTAL 
CHOLESTEROL(TABLE 32) 
TOTAL 
CHOLESTEROL
SERUM URIC ACID IN mg/dl 
    3.1-5.0 
QUARTILE1
5.1-7.0 
QUARTILE2
7.1-9.0 
QUARTILE3 
>9.0  
QUARTILE4
<100 mg/dl 1 0 0 1 
101-200 mg/dl 12 23 19 1 
201-300 mg/dl 0 7 6 3 
>300 mg/dl 0 1 1 0 
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FIGURE  26: There was no significant association between serum total 
cholesterol levels and uric acid. 
COMPARISON OF NORMOURICEMIC AND HYPERURICEMIC 
GROUPS BASED ON TOTAL CHOLESTEROL LEVELS 
(TABLE 33) 
Variables Hyperuricemia 
Non- 
Hyperuricemia
Difference
B/W H 
& NH 
‘t’ df Sig. 
Mean SD Mean SD 
Cholesterol 193.4 46.0 174.59 38.2 18.5 1.877 73 P>0.05 
 
There was no significant difference in the total cholesterol levels between the 
two groups. 
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COMPARISON OF URIC ACID LEVELS WITH BODY MASS INDEX 
(TABLE 34) 
BMI 
URIC ACID IN mg/dL 
    3.1-5.0 
QUARTILE 1 
 5.1-7.0 
QUARTILE2 
7.1-9.0 
QUARTILE3 
 >9 
QUARTILE4
20.1-25 13 19 19 3 
25.1-30 0 10 5 2 
>30 0 2 2 0 
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FIGURE 27: there was no significant association between uric acid levels and 
BMI.  
 
 
 
75 
 
Table 35. Comparison of Hyperuricemia and Non-Hyperuricemia cases 
according to  their age, window period and related Bio- chemical variables. 
Variables 
Hyperuricemia Non- Hyperuricemia Difference
B/W H 
& NH 
‘t’ df Sig. 
Mean SD Mean SD 
Age 
(years) 64.2 7.2 50.8 10.9 13.4 6.297 73 P<0.001 
Window 
(Days) 4.2 1.7 3.9 1.5 0.3 0.707 73 P>0.05 
 
Pulse rate 88.4 24.2 81.4 11.2 7.0 1.582 73 P>0.05 
 
Cholester
ol 
193.4 46.0 174.59 38.2 18.5 1.877 73 P>0.05 
TGL 171.1 46.9 144.4 36.2 26.7 2.741 73 P<0.01 
BMI 24.9 2.5 24.6 2.9 0.3 0.485 73 P>0.05 
SBP 124.9 34.3 131.1 15.8 6.2 0.947 73 P>0.05 
DBP 76.9 24.4 79.2 9.4 2.3 0.517 73 P>0.05 
TIMI 6.5 2.1 1.7 1.4 4.8 11.610 73 P<0.001 
Uric acid levels showed  a positive correlation with age, Triglyceride levels, 
Killip class and TIMI risk scores. It also showed a significant association with 
Diabtes and Hypertension. 
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COMPARISON OF EJECTION FRACTION WITH URIC ACID 
LEVELS (TABLE 36) 
EJECTION 
FRACTION 
SERUM URIC ACID IN mg% 
3.1-5.0 5.1-7.0 7.1-9.0 >9.0 
25.1-30.0 0 0 3 2 
30.1-35.0 0 0 4 1 
35.1-40.0 0 12 11 1 
40.1-45.0 8 14 4 0 
45.1-50.0 4 2 3 0 
>50.0 1 2 0 0 
 
 
FIGURE 28: Lower ejection fraction was associated with higher uric acid 
quartiles. 
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FIGURE 29: All patients with severe LV dysfunction had uric acid>7 mg/dl 
while only 25% of the subjects with mild LV dysfunction had hyperuricemia 
 All patients with LV ejection fraction< 30% had sustained anterior wall 
MI. among the subjects with moderate and severe LV dysfunction, 45% of them 
had anterior wall MI. All 3 patients with LBBB had moderate LV dysfunction. 
72% of the subjects with mild LV dysfunction had Inferior wall MI. 
 None of the patients with normal  uric acid levels had severe LV 
dysfunction whereas 16.7% of patients with hyperuricemia suffered severe LV 
dysfunction. 
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FIGURE 30 
VENTRICULAR TACHYCARDIA
COMPLETE HEART BLOCK
SUDDEN CARDIAC ARREST
ACUTE KIDNEY INJURY
CARDIAC FAILURE
FAILED THROMBOLYSIS
VENTRICULAR SEPTAL 
RUPTURE
INTRACRANIAL BLEED
REINFARCTION
PAPILLARY MUSCLE 
DYSFUNCTION
 
 Among the study group, 21 subjects developed some sort of 
complication. The mortality among those who had complications during 
hospital stay was 23%. 3.3% of the study population experienced arrhythmias 
during hospital stay. The most common among them was ventricular 
tachycardia. The majority of the arrhythmias occurred on the day of admission.  
20% of those who sustained arrhythmias died. Two patients had ventricular 
septal rupture and both went in for severe LV dysfunction and died. Totally 
18% of the patients went in for cardiac failure. The short term mortality among 
them was 23%. 
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COMPARISON OF INCIDENCE OF COMPLICATIONS IN 
HYPERURICEMIA GROUP WITH NORMAL URIC ACID GROUP 
(TABLE 37) 
Complications Acute STEMI Sr uric acid χ2 df Sig. 
Hyper Non Hyper Total 
A 2 2 3 
23.496 12 P<0.05 
AKI,F 1 0 1 
CHB 1 0 1 
CHB,VSR 1 0 1 
VT 7 0 7 
FT,F 1 0 1 
FT,VT,F 1 0 1 
ICH 1 0 1 
RS 1 0 1 
VSR 1 0 1 
PMD 1 0 1 
F 3 0 3 
Nil 1 0 1 
Total 21 34 53 
 
 This table shows the significant association of hyperuricemia with 
complications in STEMI. (A- Sudden cardiac arrest, F- Failure, AKI –Acute 
Kidney Injury, VSR- Ventricular septal rupture, PMD- Papillary muscle 
dysfunction, FT- Failed Thrombolysis, R-Reinfarction, S-Shock, ICH Intracranial 
hemorrhage, VT-Ventricular Tachycardia, CHB-Complete Heart Block) 
          When the uric acid levels on day 1 and day 3 were compared, 21 patients 
had raised uric acid levels on day 3.   71% of subjects with adverse cardiac events 
presented with higher uric acid levels on day 3 whereas only 11% of patients who 
were uneventful after thrombolysis presented with higher levels on day 3.             
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COMPARISON OF MORTALITY IN NORMAL URIC ACID AND 
HYPERURICEMIA GROUPS(TABLE 38) 
 NORMAL URIC ACID HYPERURICEMIA GROUP
TOTAL   
SUBJECTS 44 31 
NO OF 
DEATHS 1 5 
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FIGURE 31:Mortality was higher in patients with hyperuricemia (12.8%) when 
compared to subjects with normal uric acid levels.(2.7%) 
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CORRELATION OF URIC ACID LEVELS WITH MORTALITY 
(TABLE 39) 
 
SERUM URIC ACID IN mg/dl 
3.1-5.0 5.1-7.0 7.1-9.0 >9.0 
TOTAL 
SUBJECTS 13 31 26 5 
NO OF 
DEATHS 0             1 2 3 
 
FIGURE 32: Patients with uric acid level >9 mg/dl had significant mortality 
rates when compared to those in  lower quartiles. 
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Analysis and Interpretations of Serum uric acid as an Odd for STEMI. 
Table-40. Risk factors as an Odd for   Hyperuricemia. 
Risk 
Factors 
Acute STEMI Sr uric acid
χ2 df Sig. OR 
95% CI 
Hyper Non Hyper Total
Lower Upper 
Yes 31 14 45 
12.856 1 
P< 
0.001 
6.089 2.182 16.992 No 8 22 30 
Total 39 36 75 
The table 41 explains how far the risk factors were associated with 
hyperuricemia in STEMI cases. The risk factors such as Diabetes, Hypertension 
and DM+HT were strongly associated with hyperuricemia (P<0.001) with an 
Odd’s ratio of 6.089. 
 
Table-41. Hyperuricemia as an Odd for Complications.  
 
Sr Uric 
acid 
STEMI Complications
χ2 df Sig. OR 
95% CI 
Yes No Total Lower Upper 
Hyper 20 19 39 
18.883 1 
P< 
0.001 
17.895 3.767 85.004 Non Hyper 2 34 36 
Total 22 53 75 
The table 42 explains how far Hyperuricemia was associated with complications 
in STEMI. Hyperuricemia  significantly correlated with complications (P<0.00) 
and the same was as an Odd for complications 17.895 times.  
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DISCUSSION 
URIC ACID AND GENDER 
 Out of the 75 patients studied, the mean uric acid in the total population 
was 6.31mg/dl , of which men had higher mean uric acid level(6.74 mg/dl) 
when compared to women(5.49 mg/dl). But there was no statistical significance 
between the two groups(p>0.05).  
 Similar results have been shown by Dharma et al38 (Journal of Clinical 
and Experimental Cardiology, March 25,2012) in a study done in Indonesia. 
Similarly, a study by Nadkar et al(JAPI, Vol 56, Oct 2008)9 has revealed no 
difference in uric acid levels between males and females.  This is in contrast to 
the NHANES study (JAMA, May 10,2000) where men had significantly higher 
uric acid than women. 
URIC ACID AND AGE 
 The mean age in the study group was 57.55 years in men and 66.04 years 
in women (figure 2). 
 The mean age of onset of cardiovascular event was higher in females than 
in males.  
 In our study , it was observed that uric acid levels increased with age in 
men but not in women (figure 3&4) 
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 Zoppini et al (Diabetes Care, Volume 32, Sep 2009) showed similar 
results , where older, hypertensive men, compared to their female counterparts, 
had higher uric acid levels43. This is in contrast to the NHANES  I study(JAMA 
2010) and the LIFE study   ( Hoeiggen et al, Kidney International, Vol 65, 
2004) , which showed that uric acid increased with age only in women and this 
association could not be found in men45. Nadkar et al has reported no significant 
association between serum uric acid and age in both genders.  
 The prevalence of hyperuricemia in our  study was 60% in patients with 
STEMI, which is higher than that seen in a Thai study where it was only 
49%(Vitoon et al)36  .In the studied population, 50.77% of men and 60% of 
women had hyperuricemia .(figure 5) 
ASSOCIATION OF URIC ACID WITH RISK FACTORS                     
 In our study, the presence of diabetes and hypertension  was 
significantly associated with hyperuricemia .(figure 21&22) 
 In  two studies that dealt with association of acute myocardial infarction 
with hyperuricemia, the authors (Nadkar et al and Dharma et al) did not find 
any statistically significant association between these two factors and 
hyperuricemia. But in LIFE study that studied the effects of losartan and 
atenolol in hypertensive patients, there was a significant association between 
diabetes and hyperuricemia45. Similarly the NHANES study also found a 
significant correlation of hyperuricemia with diabetes and hypertension in both 
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males and females. Alexander Strasak has also showed that hypertensive 
subjects have slightly increased uric acid levels when compared to 
normotensives ,in a prospective study conducted on Austrian men12. 
 Similar to many other studies, our study also shows a positive correlation 
between triglyceride level with hyperuricemia.(figure 25). But a negative 
correlation has been obtained with cholesterol levels. Li Chen et al brought out 
similar results with triglyceride while no association was found with cholesterol 
levels10.  We also found that uric acid levels increased with increase in number 
of risk factors.(figure 24) 
 Our study did not show any positive correlation of smoking with 
hyperuricemia. (table 28)Dharma et al has shown similar results38.  
 Body mass index showed no statistically significant association with uric 
acid levels. But it was observed that all subjects with low BMI (<23kg/m2)  had 
lower uric acid levels(3-5 mg/dl). As previously mentioned, South East Asian 
population is prone for CAD even in the presence of low BMI. Many studies 
done on this population have proved this effect. According to our observation, 
uric acid may not be useful in identifying cardiovascular risk in this subset with 
low body mass index. On the contrary,Zoppini et al has found significant 
association of uric acid levels with Body mass index45. But this study included 
only diabetic individuals, whereas our present study included a heterogenous 
population. 
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 URIC ACID AND PROGNOSTIC INDICATORS 
 In the present study, anterior wall MI constituted about  40% of total MIs.    
60% of females had inferior wall MI while   45% of males had anterior wall MI. 
In our study, anterior wall MI was strongly associated with hyperuricemia. But 
Dharma et al (JCEC,2012) found no statistically  significant difference in the 
type of myocardial infarction associated with hyperuricemia and low uric acid 
levels38. In previous studies ,anterior location of myocardial infarction has been 
proved to be a poor prognostic indicator in acute myocardial infarction.  
 In our study, Killip Class III and IV were commonly associated with 
higher uric acid levels than class I and II.(figure 16).  Killip class showed a 
linear correlation with uric acid levels.( figure 17).  8% of the subjects in the 
present study were in Killip class IV and hyperuricemia was found in all these 
patients.  In a meta analysis of prognostic studies ( Kojima et al,Croat MED J, 
March 2012),Trkulja et al has highlighted that some of the studies that 
compared the Killip staging with uric acid levels have brought out a strong 
correlation between Killip III and IV stages with higher uric acid levels, though 
many studies failed to match the high and low uric acid patients, in respect to 
the major outcome risk factors ( age, Killip class or renal function)8. Nadkar et 
al has also brought out similar correlations. This result shows the prognostic 
significance of uric acid in ST Elevation MI. 
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 We have found a significant association of TIMI risk score in  STEMI 
with uric acid . Higher  TIMI scores were associated with higher uric acid 
quartiles. Figure 18 and 19 show the relationship of TIMI scores with uric acid 
levels in males and females.  David A. Morrow et al  has proposed a bed side 
clinical score for prognostic assessment of fibrinolytic eligible patients with 
STEMI. An increase in 30 day mortality was observed in subjects with higher 
TIMI scores 33more than 8. In our study hyperuricemia was significantly 
associated with higher TIMI scores, both in males and females. 
 In our study, the uric acid levels correlated well with ejection 
fraction.(figure 28). LV dysfunction is an important prognostic indicator in 
myocardial infarction. In our study, five patients had ejection fraction<30%. All 
patients with severe LV systolic dysfunction had uric acid levels >7 mg/dl. This 
result is similar to that of Li Chen et al, in their study on Japanese population. 
This study has also shown that persons with hyperuricemia had larger LVID10. 
But in our study, this variable was not analysed. 
 
URIC ACID AND MACE/MORTALITY 
 In our study involving 75 subjects the mortality was 6.6% .  All deaths 
occurred in males. Most of the complications occurred during the first day of 
presentation. One patient died on the day of admission due to arrhythmia and 
cardiac arrest. The other death that occurred within 3 days was due to 
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intracranial bleed.   The other three patients had an extended hospital stay and 
died due to cardiac failure.   It was found that the mortality in the hyperuricemic 
group (>7 mg/dl) was 15.15% ,while the mortality in the normal uric acid group 
was only 2.2%,(figure 31) which was statistically significant.  The mortality in 
the uric acid quartile 7 – 9 mg/dl  was 8%   while the mortality rose to 80% in 
subjects with uric acid levels more than 9 mg/dl(figure32). Similar results have 
been observed in many studies conducted in patients with acute coronary 
syndromes. Nadkar et al reported hyperuricemia in all six deaths that occurred 
after MI.  Dharma et al reported that uric acid levels >7 mg/dl was the strongest 
independent predictor of mortality . 
 The major cardiac adverse events (MACE) that occurred during the 
follow up were cardiac arrhythmias, most commonly ventricular tachycardia, 
sudden cardiac arrest, reinfarction, cardiac failure, ventricular septal rupture , 
papillary muscle dysfunction and intracerebral bleed. 21 of our subjects 
experienced one or the other complication during the course of stay in the 
hospital. Of these 21 patients, 15 had higher levels of uric acid on the third day, 
2 subjects succumbed before the third day, and the other 6 had lower uric acid 
levels on the third day when compared to the day of admission.  All subjects 
who went in for cardiac failure had higher uric acid levels on day 3.   There was 
a significant association between the MACE and hyperuricemia.  48.72% of 
subjects with hyperuricemia experienced complications whereas only 5.5% of 
89 
 
the subjects with normal uric acid levels had complications, which was 
statistically significant. All subjects who had uric acid levels >7.9mg/dl 
experienced complications and among the 5 whose uric acid level was> 9 
mg/dl, three patients succumbed.   The highest uric acid level observed was 10.2 
mg/dl, in a patient with ventricular septal rupture. He presented with Killip class 
IV and subsequently died of cardiac failure.  This patient had a uric acid level of 
11.2 on the third day.    
 Kojima et al has come up with similar results in his metaanalysis stating 
that hyperuricemia is associated with higher occurrence of short term and 
medium term major adverse cardiac events8.  
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CONCLUSION 
 Uric acid is an old molecule with new applications and it has been studied 
in various metabolic diseases, pulmonary hypertension and renal failure.   In 
this study, it has been found that uric acid has a significant correlation with age, 
anterior location of MI, Killip class and TIMI risk score in STEMI and  also 
with short term adverse cardiac events and cardiovascular mortality and hence, 
can be considered as an independent prognostic marker in acute myocardial 
infarction.    
LIMITATIONS OF THE STUDY 
 In this study, the female population was limited and hence the results 
cannot  be extrapolated to the general population. It was only a short term 
prognostic study and more data will be made available if long term major 
adverse cardiac events are taken into account.   
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                           SCOPE FOR FUTURE RESEARCH                 
 The role of Xanthine oxidase inhibition in the treatment of myocardial 
infarction and heart failure needs to be studied .  Among the older drugs used in 
reducing cardiovascular mortality, three drugs have been proved to reduce the 
levels of uric acid: they are 1. Fenofibrate; 2. Statins and 3.Losartan35 . 
Allopurinol has been studied on a smaller population with heart failure and long 
term improvements in endothelial function has been demonstrated.  A 
significant improvement in ejection fraction and LV diameter was also 
observed35. But these results could not be extrapolated to a larger population. 
Large scale trials with definite end points are required to address this issue. 
Whether the clinical improvement is due to uric acid reduction or due to 
xanthine oxidase inhibition also needs to be studied. 
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ABBREVIATIONS 
• ACC – American College of Cardiology 
• ACS – Acute Coronary Syndrome 
• AKI – Acute Kidney Injury 
• ASMI – Anteroseptal Myocardial Infarction 
• AWMI – Anterior Wall Myocardial Infarction 
• BMI – Body Mass Index 
• BNP – Brain Natriuretic Peptide 
• CAD-Coronary Artery Disease 
• CVD – Cardiovascular Disease 
• DM – Diabetes mellitus 
• e NOS – Endothelial Nitric Oxide Synthase 
• GISSI - Gruppo Italiano per lo Studio della     Sopravvivenza 
nell’Infarto Miocardio   
• GRACE  - Global Registry of Acute Coronary Events 
• Hs-CRP – High sensitive C Reactive Protein 
• HT – Hypertension 
• IHD – Ischaemic Heart Disease 
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• IL-6 – Interleukin 6 
• IWMI – Inferior Wall Myocardial Infarction 
• LBBB – Left Bundle Branch Block 
• LDL – Low Density Lipoprotein 
• LDL c – Small dense oxidised LDL 
• Lp(a) – Lipoprotein a 
• LV – Left Ventricle 
• MACE – Major Adverse Cardiac Events 
• MET – Metabolic equivalent 
• MI – Myocardial Infarction 
• MPO – Myeloperoxidase 
• NO – Nitric Oxide 
• NSTEMI – Non ST Elevation Myocardial Infarction 
• RHD – Rheumatic Heart Disease 
• ROS – Reactive Oxygen Species 
• S ICAM 1- Soluble Intercellular Adhesion Molecule-1 
• STEMI – ST Elevation Myocardial Infarction 
• SUA – Serum Uric Acid 
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• TGL – Triglyceride 
• TIMI – Thrombolysis In Myocardial Infarction 
• UA – Unstable Angina 
• URAT 1- Urate Anion Exchanger 1 
• VF – Ventricular Fibrillation 
• VSR – Ventricular Septal Rupture 
• VT – Ventricular Tachycardia 
• XOR – Xanthine Oxidoredutase 
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                           PROFORMA 
NAME                                                      AGE/SEX                                     
IP NO                                                          OCCUPATION               
WINDOW PERIOD 
 SYMPTOMS 
RISK FACTORS 
♦ Diabetes 
♦ Systemic Hypertension 
♦ Smoking 
♦ Alcoholism 
♦ Family H/O CAD 
8. PAST HISTORY 
 Chronic drug intake 
 Known CAD 
 H/O ATT  
 H/O Chronic Kidney Disease 
 H/O Hypothyroidism 
 Presence of myeloproliferative diseases 
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9. CLINICAL EXAMINATION FINDINGS 
¾ PULSE RATE 
¾ BP 
¾ JVP 
¾ BASAL CREPTS 
¾ S3 GALLOP 
 
 ECG IN ALL LEADS: 
 TYPE OF MI: 
 KILLIP CLASS:  
 THROMBOLYSIS: 
 HEIGHT:       WEIGHT:           BMI: 
 TIMI SCORE: 
10. INVESTIGATIONS 
                 a) Blood Sugar 
                 b) Blood Urea 
                 c)Serum Creatinine 
                d) Total Count:             ; Differential count: 
                e) Hemoglobin    
                f)  Erythrocyte Sedimentation Rate 
                g)  Serum Cholesterol 
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                 h) Serum Triglyceride 
                 i) Serum Uric Acid  on day 1: 
                                                   on day 3: 
               j) Ejection Fraction: 
10. HOSPITAL STAY:  
11. COMPLICATIONS  
12. MORTALITY: 
Sl No NAME AGE SEX WINDOW PR BP KILLIP TYPE DM HTN SMOKING FAMILY no of risk CHOL TGL BMI TIMI UA 1 UA 2 EF COMPL STAY MORTALITY
1 MUTHURAJ 75 M 2.5 104 160/90 I AW Y Y N N 2 182 158 22.7 8 7.4 6 40.8 N 10 N
2 ACHIAMMAL 65 F 3 72 140/90 I AS Y N N N 1 186 191 24.7 4 6.3 6.2 42 N 7 N
3 SAMIKANNU 60 F 4 62 120/80 I IW N N N N 0 192 154 25 0 5.4 5.6 48 A 8 N
4 HARIKRISHNAN 52 M 2.5 60 130/80 II AW N Y N N 1 173 126 21.78 4 7.2 5 38.5 N 12 N
5 GANAPATHY 53 M 2 72 120/80 I AS Y N Y N 2 182 152 23.82 2 5.9 4.2 42.5 N 7 N
6 THANGAIYAH 47 M 5 88 150/70 I AS N Y Y N 2 119 112 20.1 4 6.9 5.2 40 N 10 N
7 PALRAJ 40 M 3 78 120/90 I IW N N N N 0 96 116 21.2 0 4.4 5 44 N 6 N
8 PETCHIMUTHU 75 M 2 80 130/90 I AW Y N N N 1 140 124 23.61 5 7.1 6.2 41.4 N 6 N
9 SURESH 37 M 4 72 130/80 I IW N N Y Y 2 184 151 21.73 0 4.3 4.2 46.6 N 7 N
10 PREMKUMAR 24 M 4 80 130/90 I AW N N Y Y 2 172 86 23.78 1 5.1 5 40.4 N 8 N
11 PARAMANAND 66 M 1 100 160/90 II AW N Y N N 1 185 110 23.2 8 8.1 8.3 36.8 F 6 N
12 SIVAN PANDI 46 M 5 78 130/80 I AW N N Y N 1 192 154 24.76 2 6.9 5.6 42.8 N 6 N
13 PARVATHY 50 F 3 88 110/70 I AS N N N N 0 184 140 24.5 1 5.2 4.9 44.2 N 5 N
14 KRISHNAN 45 M 2 82 150/100 I IW N N Y N 1 176 142 23.43 0 4.3 5 43 N 6 N
15 VINCENT 38 M 2 98 130/90 I AS N N Y Y 2 303 1272 33.12 1 5.9 5.2 43.8 N 8 N
16 HABEEB MOHD 66 M 6 110 100/80 IV AW Y Y Y Y 3 202 164 24.83 9 10.2 11.8 25 VSR 7 Y
17 GNANA DURAI 55 M 5 78 130/80 I AS N N Y N 1 156 136 23.33 2 4.4 4.3 44.3 N 6 N
18 ESAKKIMUTHU 67 M 7 120 180/120 III AW N Y Y N 2 213 185 29.76 9 8 8.7 34.8 FT,F 7 N
19 ADHINARAYANA 45 M 1 62 130/80 I IW PW Y N N Y 2 227 224 32.7 1 5.3 5.1 49.6 N 6 N
20 MOHD UZHAIM 58 M 2 86 170/90 II AW Y Y N N 2 177 121 22.14 4 7.8 7.2 39.8 N 7 N
21 SHANKARASUBU 54 M 2 86 150/80 III LW PW Y N Y N 2 213 272 26.22 3 6.4 5.8 42.5 N 9 N
22 PARAMASIVAN 72 M 5 32 100/80 III AW N Y Y N 2 92 182 23.7 7 10 10.8 26 CHB  VSR 8 Y
23 ANNAMALAI 65 M 6 120 100/70 III LBBB Y N N N 1 394 154 24.87 9 8.6 8.8 31.7 F 12 N
24 SAHASRANAMAM 65 M 3 100 140/90 II AW Y N Y N 2 191 272 23.8 7 7.5 6.2 39.4 VT 7 N
25 VEL THEVAR 60 M 6 108 60/? IV IW N N Y N 1 167 132 23.86 8 7.6 7.3 35.9 VT 10 N
26 KADARKARAI 75 M 4 80 130/80 I AW Y N Y N 2 198 194 24.4 5 10 - - ICH 3 Y
27 AYYAPPAN 35 M 3 84 100/80 I IW PW N N N Y 1 130 88 24.82 1 3.8 3.4 49.8 N 6 N
28 RAMESH 58 M 5 72 150/100 II AW N Y Y N 2 234 212 30.33 5 7.6 7.4 39.2 A 7 N
29 GOPAL 59 M 5 82 140/90 II AW N Y Y N 2 163 226 24.56 6 7.5 9.6 30 R,S 14 Y
30 MURUGAN 55 M 3 100 160/90 II AW Y Y Y N 3 167 108 23.54 5 7.6 5.8 37.2 N 7 N
31 SHENBAGAVALLI 48 M 4 104 150/100 I AW N Y N N 1 183 139 23.08 4 7.2 6.7 48.4 N 6 N
32 KALIAMMAL 55 F 6 76 170/60 I IW Y Y N Y 3 227 140 26.8 2 5.2 5.4 50 N 7 N
33 PUSHPAM 65 F 8 120 120/70 I AW Y Y N N 2 176 156 20.76 7 6.8 6.1 39.4 N 12 N
34 LAKSHMI 65 F 3 82 140/90 I AS N N N N 0 232 155 27.54 3 6.2 6 412 N 7 N
35 GNANA DURAI 55 M 5 78 130/90 I AS N N Y N 1 156 106 22.87 2 4.2 3.6 42.3 N 6 N
36 DHIRAVIYAM 70 M 5 80 120/80 I AW N N N N 0 139 111 23.7 4 6.7 5 38.5 N 8 N
37 MAHARAJAN 25 M 7 86 140/80 I AW N N Y Y 2 218 197 24.26 2 6.7 5.2 40.8 N 7 N
38 AKKAMMAL 60 F 1 58 130/90 II IW/RV/PW N N N N 0 188 190 24.71 2 6.5 6 42 N 10 N
39 AYYAKANNU 72 M 4 82 90/60 II IW/PW N N Y N 1 205 253 23.6 7 7.8 5.2 46 N 8 N
40 SANGILIKALAI 70 M 6 80 50/? IV AW Y N N N 1 186 105 22.89 9 8.4 8 32 VT 10 N
41 MANJULA 38 F 4 98 140/90 I IW/RV Y N N Y 2 148 117 22.92 1 4.2 4 56 N 5 N
42 SAKTHIVEL 62 M 5 98 140/70 I AW N N N N 0 162 145 23.8 2 6.1 5.8 40 N 6 N
43 RAMAIAH 58 M 3 82 130/70 II IW N N Y N 1 202 156 28.45 2 5.4 5.1 52 N 7 N
44 MEERAN 65 M 5 98 80/50 IV AW N Y Y N 2 234 187 22.89 9 8.2 10.2 26 FT,VT,F 14 N
45 MUTHU KUMAR 60 M 4 82 120/70 I IW Y N N N 1 187 167 23.32 1 4.2 4.3 42 N 7 N
46 SRINIVASAN 56 M 6 100 170/100 I AW N Y Y N 2 156 123 23.13 3 6.8 5 35.8 N 6 N
47 VELAYUTHAM 54 M 4 108 150/70 II LBBB Y Y N N 2 198 156 23.54 7 8.2 8.5 34 F 6 N
48 SHEIKH 62 M 6 98 140/70 I AW N Y Y N 2 208 187 25.43 3 6.9 5.6 42 N 8 N
49 VEERASAMY 65 M 4 72 130/80 I AW N N Y N 1 176 145 25.89 4 6.8 5 38.7 N 6 N
50 ARUNACHALAM 59 M 6 88 150/80 I IW N Y N N 1 167 132 22.34 2 5.6 4.2 52 N 6 N
51 JEYASEELAN 63 M 5 108 100/60 III AS Y Y N N 2 228 234 31.3 7 7.9 8.4 39 F 10 N
52 PODUMPONNU 68 F 4 32 90/60 III IW/RV/PW N N N N 0 176 210 22.21 7 7.1 6.2 44 N 7 N
53 MADHAVAN 56 M 6 110 130/70 II AS Y N Y N 2 189 167 28.67 7 7.3 7 40 N 8 N
54 MARKANDAN 60 M 3 82 140/70 I IW N Y N N 1 178 146 20.25 1 4.2 4 43.7 N 7 N
55 SATHYAMOORTHY 68 M 4 98 180/90 II AS N Y N Y 2 187 124 25.67 6 7 5.4 42 N 7 N
56 JESURAJ 55 M 3 80 130/80 I IW PW N N Y N 1 163 134 23.89 0 5.2 4.8 39.7 N 6 N
57 MOOKAN 67 M 4 108 150/70 III LBBB N Y Y N 2 212 152 26.56 8 9.2 9.3 37 F 8 N
58 SYED ALI 59 M 6 64 80/60 IV IW RV PW Y Y Y Y 4 256 312 29.84 7 7.3 5.4 41 N 7 N
59 MURUGAN 49 M 3 88 130/70 I AS Y N N N 1 162 190 27.91 2 5.8 5 39 N 6 N
60 MANIKANDAN 55 M 5 32 60/40 IV IW PW N N N Y 1 139 198 28.12 6 7.9 6 45.9 CHB 7 N
61 GANAPATHY 60 M 6 92 140/80 I IW N N N N 0 162 149 27.86 2 5.1 4 42 N 8 N
62 VENKATESAN 55 M 3 58 100/60 I AS Y N N N 1 176 125 29.13 2 6.4 6.5 40 N 9 N
63 KALIAPPAN 67 M 5 108 90/60` III AW Y N Y N 2 190 178 26.74 12 8.8 9.7 24 F 12 N
64 GOMATHINAYAGAM 71 M 6 110 150/90 II AS N N Y N 1 264 213 27.23 8 9.2 9.8 31 AKI, F 9 N
65 NARAYANAN 75 M 2.5 104 160/110 I AW Y Y N N 2 186 154 23.7 8 7.4 7.9 36.8 F 10 N
66 MEENAMMAL 68 F 4 68 140/100 I IW Y N N N 1 176 121 23.7 4 6 6.2 42 N 7 N
67 RAJAVEL 60 M 4 62 120/80 I IW N N N N 0 192 124 23.58 0 4.4 4.2 48 N 8 N
68 CHOKKALINGAM 52 M 2.5 60 130/80 II AW N Y N N 1 173 126 24.2 4 7.2 5 38.5 N 12 N
69 CHANDRASEKAR 53 M 2 72 120/80 I AS Y N Y N 2 182 132 23.8 2 5 4.2 42.5 N 7 N
70 KANDEEPAN 62 M 6 102 110/70 II AS N N Y N 1 119 172 22.62 6 6.4 8.2 37 A 10 N
71 MANOHAR 40 M 3 78 120/90 I IW N N N N 0 108 126 22.52 0 4.5 4 44 N 6 N
72 VELAYUTHAM 75 M 2 80 130/90 I AW Y N N N 1 140 124 23 5 7 6.2 37.4 N 6 N
73 DILIP KUMAR 42 M 4 72 130/80 I IW N N Y Y 2 184 121 21.82 0 4.2 4.2 46.6 N 7 N
74 ENAMUTHU 70 M 5 110 130/90 II AW Y N Y Y 3 172 186 24.78 9 8.8 VT,A 1 Y
75 SAKTHIVEL 59 M 6 99 120/70 II AS N Y Y N 2 187 174 23.98 5 7 7.2 39 N 10 N
